JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 18, 2009; DOI: 10.1124/jpet.108.147793


0022-3565/09/3292-625-633$20.00
JPET 329:625-633, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.147793v1
329/2/625    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Theile, J. W.
Right arrow Articles by Morrisett, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theile, J. W.
Right arrow Articles by Morrisett, R. A.

NEUROPHARMACOLOGY

Role of 5-Hydroxytryptamine2C Receptors in Ca2+-Dependent Ethanol Potentiation of GABA Release onto Ventral Tegmental Area Dopamine Neurons

Jonathan W. Theile, Hitoshi Morikawa, Rueben A. Gonzales, and Richard A. Morrisett

Cell and Molecular Biology (J.W.T., H.M., R.A.M.), Waggoner Center for Alcohol and Addiction Research (H.M., R.A.G., R.A.M.), Section of Neurobiology (H.M.), and Division of Pharmacology and Toxicology (R.A.G., R.A.M.), College of Pharmacy, University of Texas, Austin, Texas

Activation of ventral tegmental area (VTA)-dopaminergic (DA) neurons by ethanol has been implicated in the rewarding and reinforcing actions of ethanol. GABAergic transmission is thought to play an important role in regulating the activity of DA neurons. We have reported previously that ethanol enhances GABA release onto VTA-DA neurons in a brain slice preparation. Because intraterminal Ca2+ levels regulate neurotransmitter release, we investigated the roles of Ca2+-dependent mechanisms in ethanol-induced enhancement of GABA release. Acute ethanol enhanced miniature inhibitory postsynaptic current (mIPSC) frequency in the presence of the nonspecific voltage-gated Ca2+ channel inhibitor, cadmium chloride, even though basal mIPSC frequency was reduced by cadmium. Conversely, the inositol-1,4,5-triphosphate receptor inhibitor, 2-aminoethoxydiphenylborane, and the sarco/endoplasmic reticulum Ca2+ ATPase pump inhibitor, cyclopiazonic acid, eliminated the ethanol enhancement of mIPSC frequency. Recent studies suggest that the G protein-coupled receptor, 5-hydroxytryptamine (5-HT) 2C, may modulate GABA release in the VTA. Thus, we also investigated the role of 5-HT2C receptors in ethanol enhancement of GABAergic transmission. Application of 5-HT and the 5-HT2C receptor agonist, Ro-60-0175 [({alpha}S)-6-chloro-5-fluoro-{alpha}-methyl-1H-indole-1-ethanamine fumarate], alone enhanced mIPSC frequency of which the latter was abolished by the 5-HT2C receptor antagonist, SB200646 [N-(1-methyl-5-indoyl)-N-(3-pyridyl)urea hydrochloride], and substantially diminished by cyclopiazonic acid. Furthermore, SB200646 abolished the ethanol-induced increase in mIPSC frequency and had no effect on basal mIPSC frequency. These observations suggest that an increase in Ca2+ release from intracellular stores via 5-HT2C receptor activation is involved in the ethanol-induced enhancement of GABA release onto VTA-DA neurons.


Received for publication October 22, 2008
Accepted February 17, 2009.

Address correspondence to: Jonathan Theile, University of Texas, PHAR-Pharmacology, 1 University Station, A1915, Austin, TX 78712-0125. E-mail: jontheile{at}mail.utexas.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.